| In millions, except per share items | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-K |
| Revenues: |
| Australia | 10 | | | 8 | | | | |
| Other | 921 | | | 881 | | | | |
| Total revenues [+] | 931 | 996 | 941 | 889 | | 934 | 881 | |
| Products | | 991 | | | | | | |
| Other | | 5 | | | | | | |
| Revenue growth [+] | 4.7% | | 0.7% | 0.9% | | | | |
| Australia | 25.0% | | | | | | | |
| Ophthalmic Pharmaceuticals | 3.9% | | -13.0% | -4.9% | | | | |
| Cost of goods sold | 372 | 418 | 379 | 348 | | 366 | 333 | |
| Gross profit | 559 | 578 | 562 | 541 | | 568 | 548 | |
| Gross margin | 60.0% | 58.0% | 59.7% | 60.9% | | 60.8% | 62.2% | |
| Selling, general and administrative | 418 | 386 | 368 | 343 | | 358 | 318 | |
| Research and development | 77 | 78 | 75 | 77 | | 71 | 67 | |
| Other operating expenses | 9 | 7 | -1 | 2 | | 3 | 2 | |
| EBITDA [+] | 89 | 107 | 154 | 149 | | 170 | 191 | |
| EBITDA growth | -40.3% | | -9.4% | -22.0% | | | | |
| EBITDA margin | 9.6% | 10.7% | 16.4% | 16.8% | | 18.2% | 21.7% | |
| Depreciation and amortization | 34 | | 34 | 30 | | 34 | 30 | |
| EBITA | 55 | 107 | 120 | 119 | | 136 | 161 | |
| EBITA margin | 5.9% | 10.7% | 12.8% | 13.4% | | 14.6% | 18.3% | |
| Amortization of intangibles | 57 | 56 | 64 | 65 | | 77 | 76 | |
| EBIT [+] | -2 | 51 | 56 | 54 | | 59 | 85 | |
| EBIT growth | -103.7% | | -5.1% | -36.5% | | | | |
| EBIT margin | -0.2% | 5.1% | 6.0% | 6.1% | | 6.3% | 9.6% | |
| Non-recurring items | | | | | | 1 | | |
| Interest expense, net [+] | 47 | 44 | 43 | 20 | | | | |
| Interest expense | 50 | 47 | 44 | 20 | | | | |
| Interest income | 3 | 3 | 1 | | | | | |
| Other income (expense), net [+] | -6 | -9 | 14 | -5 | | 9 | -8 | |
| Gain (loss) on foreign currency transactions | -6 | | 14 | -5 | | 9 | -8 | |
| Pre-tax income | -55 | -2 | 27 | 29 | | 67 | 77 | |
| Income taxes | 33 | -2 | 20 | 6 | | 21 | 47 | |
| Tax rate | | 100.0% | 74.1% | 20.7% | | 31.3% | 61.0% | |
| Minority interest | 2 | -1 | 2 | 3 | | 2 | 3 | |
| Net income | -90 | -1 | 5 | 20 | | 44 | 27 | |
| Net margin | -9.7% | -0.1% | 0.5% | 2.2% | | 4.7% | 3.1% | |
| |
| Basic EPS [+] | ($0.26) | $0.00 | $0.01 | $0.06 | | $0.13 | $0.08 | |
| Growth | -550.0% | | -88.6% | -25.9% | | | | |
| Diluted EPS [+] | ($0.26) | $0.00 | $0.01 | $0.06 | | $0.13 | $0.08 | |
| Growth | -550.0% | | -88.6% | -25.9% | | | | |
| |
| Shares outstanding (basic) | 350 | 350 | 350 | 350 | | 350 | 350 | |
| Growth | 0.0% | | 0.0% | 0.0% | | | | |
| Shares outstanding (diluted) | 350 | 350 | 350 | 350 | | 350 | 350 | |
| Growth | 0.0% | | 0.0% | 0.0% | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |